News and stories about the UNC Lineberger Cellular Immunotherapy Program
UNC Lineberger researchers are using CAR-T to create better and personalized cancer treatments in one of the largest cell therapy facilities on the East Coast.
The inaugural symposium featured talks on adoptive cellular therapy for lymphoid malignancies and novel approaches for the treatment of acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
When traditional cancer treatment options failed, Sabrina Shelton’s care team referred her to UNC for a CAR-T therapy clinical trial.
View all program news